Search

Displaying results 2391 - 2400 of 10000 in total
  1. Drug

    Oxcarbazepine

    go.drugbank.com/drugs/DB00776
    ApprovedInvestigational

    [A186011] Compared to other anti-epileptic drugs, which are generally metabolized via the cytochrome P450 system, oxcarbazepine has a reduced propensity for involvement in drug-drug interactions owing … Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.

  2. Drug

    Dalteparin

    go.drugbank.com/drugs/DB06779
    ApprovedInvestigational

    Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. … Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant.

  3. Drug

    Benzhydrocodone

    go.drugbank.com/drugs/DB15465
    Approved

    [L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse. … It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]

  4. Drug

    Ginkgo biloba

    go.drugbank.com/drugs/DB01381
    ApprovedInvestigationalNutraceutical

    [L32789] _Ginkgo biloba_ is an herbal plant that is now cultivated worldwide. It is originally native to China, and _ginkgo biloba_ extract has been used in traditional Chinese medicine for centuries. … [A232379] _Ginkgo folium_, the leaf extract of _Ginkgo biloba_, is considered an anti-dementia drug by the World Health Organization.[A232389]

    Categories: Complex Mixtures
  5. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the

  6. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO. … [L41399] In August 2022, other biosimilars CIMERLI, RAIVISIO, and RANOPTO were approved by the FDA, EC, and Health Canada respectively.[L42625,L43513,L49141]

    Products: LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE, LUCENTIS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 1.65mg/0.165ml
  7. Drug

    Fremanezumab

    go.drugbank.com/drugs/DB14041
    ApprovedInvestigational

    [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment … [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018.

    Products: AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5ML, Ajovy Filled Pen
  8. Drug

    Octreotide

    go.drugbank.com/drugs/DB00104
    ApprovedInvestigational

    [L14501] In most cases, it results from an anterior pituitary growth hormone-releasing tumor. … [L14513] In the past, octreotide has been administered solely by injection.

    Products: BYNFEZIA Pen, Siroctid 0,1 mg/ml Injektionslösung in einer Fertigspritze
  9. Drug

    Isoflurophate

    go.drugbank.com/drugs/DB00677
    ApprovedWithdrawn

    Its vapor is highly toxic and it is recommended that only solutions in arachis oil be used therapeutically. (From Martindale, The Extra Pharmacopoeia, 29th ed, p1330) … An irreversible cholinesterase inhibitor with actions similar to those of echothiophate. It is a powerful miotic used mainly in the treatment of glaucoma.

  10. Drug

    Galcanezumab

    go.drugbank.com/drugs/DB14042
    ApprovedInvestigational

    [L42060] It is unknown if galcanezumab has an effect on pregnancy outcomes. A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060] … [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache.

    Products: EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120 MG/ML, Pontevia 120 mg solution for injection in pre-filled pen